viral
infect
respiratori
tract
respons
signific
morbid
mortal
worldwid
influenza
virus
rhinovirus
hrv
adenovirus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
common
aetiolog
agent
infect
burden
diseas
caus
virus
occur
extrem
age
hospitalis
rate
among
children
similar
elderli
annual
estim
cost
influenza
alon
australian
healthcar
system
million
increas
recognit
burden
influenza
morbid
mortal
result
broaden
recommend
influenza
vaccin
unit
state
canada
recent
decad
extens
studi
identifi
hitherto
unknown
agent
aetiolog
acut
respiratori
tract
infect
ari
associ
develop
technolog
viru
detect
facilit
epidemiolog
characteris
despit
advanc
remain
case
known
respiratori
viru
identifi
ari
episod
suggest
addit
respiratori
pathogen
like
exist
support
notion
number
previous
undescrib
virus
identifi
analysi
clinic
specimen
human
respiratori
tract
sinc
human
metapneumoviru
sar
coronaviru
coronaviru
coronaviru
human
bocavirus
novel
rhinovirus
recent
describ
ki
wu
polyomavirus
sever
author
previous
report
commun
epidemiolog
viral
acut
respiratori
infect
cohort
children
year
age
within
larg
vaccin
trial
conduct
studi
viral
aetiolog
respiratori
tract
infect
experienc
healthi
commun
dwell
adult
report
symptom
ill
ili
total
healthi
adult
age
least
year
year
enrol
phase
iv
efficaci
trial
licens
season
trival
influenza
vaccin
csl
ltd
parkvil
vic
australia
conduct
march
novemb
studi
site
australia
new
zealand
clinicaltrialsgov
main
exclus
criteria
follow
allergi
vaccin
compon
medic
unstabl
clinic
condit
plan
current
pregnanc
lactat
histori
syndrom
confirm
suspect
immunosuppress
condit
current
recent
immunosuppress
therapi
concurr
particip
clinic
trial
use
investig
compound
recommend
season
influenza
vaccin
accord
guidelin
australia
new
zealand
follow
provis
written
inform
consent
particip
randomli
assign
receiv
vaccin
placebo
ratio
remind
weekli
report
symptom
ili
commenc
day
vaccin
end
novemb
particip
meet
ili
case
definit
least
one
respiratori
symptom
cough
sore
throat
runni
nose
nasal
congest
least
one
system
symptom
fever
feverish
chill
myalgia
ask
present
collect
respiratori
swab
influenza
detect
within
rct
nest
cohort
studi
involv
denomin
popul
particip
australian
studi
centr
figur
particip
site
present
ili
assess
invit
consent
particip
viru
substudi
involv
collect
one
extra
respiratori
swab
primari
phase
iv
efficaci
trial
substudi
ethic
approv
particip
substudi
site
list
acknowledg
substudi
site
particip
reimburs
time
inconveni
accord
approv
practic
respect
ethic
committe
ili
visit
nose
throat
specimen
collect
use
dri
flock
swab
initi
transport
local
hold
laboratori
frozen
specimen
return
togeth
collect
primari
studi
csl
ltd
laboratori
copan
diagnost
inc
murrieta
ca
usa
parkvil
ship
dri
ice
sever
consign
queensland
paediatr
infecti
diseas
laboratori
sampl
test
virus
includ
influenza
b
rsv
parainfluenza
virus
adenovirus
human
metapneumoviru
hmpv
picornavirus
bocavirus
coronavirus
ki
wu
polyomavirus
use
combin
multiplex
uniplex
convent
polymeras
chain
reaction
pcr
assay
particip
given
questionnair
request
inform
clinic
cours
ill
includ
symptom
experienc
along
complic
medic
treatment
sought
interrupt
usual
activ
durat
episod
repli
paid
envelop
provid
within
return
questionnair
vaccin
immunis
research
group
melbourn
presenc
absenc
detect
viru
respiratori
specimen
categoris
binari
outcom
measur
associ
sought
viru
detect
number
particip
age
sex
race
smoke
vaccin
statu
month
studi
site
variabl
use
multivari
logist
regress
model
virolog
result
organis
broad
group
none
viru
detect
picornavirus
influenza
virus
b
coronavirus
hmpv
parainfluenza
virus
rsv
adenovirus
bocavirus
polyomavirus
viru
group
associ
host
extern
variabl
describ
symptom
score
develop
hayden
et
al
trial
influenza
drug
oseltamivir
ideal
consid
labour
intens
appli
protocol
therefor
sought
encapsul
comprehens
rang
symptom
possibl
characteris
comparison
ill
episod
particip
return
questionnair
symptom
score
calcul
score
one
point
symptom
rang
minimum
necessari
meet
case
definit
maximum
associ
score
viru
isol
group
host
factor
age
sex
race
smoke
month
studi
site
variabl
consid
use
multivari
linear
regress
model
vaccin
statu
particip
includ
regress
model
known
mitig
effect
likelihood
influenza
acquisit
seeresult
measur
episod
sever
includ
medic
diagnos
complic
medic
attend
practition
type
prescript
antivir
agent
durat
episod
number
day
away
usual
activ
result
ill
report
statist
analys
conduct
use
stataic
statacorp
lp
colleg
station
tx
usa
consent
particip
substudi
obtain
attend
ill
episod
main
rct
episod
occur
particip
eight
specimen
miss
sampl
particip
includ
analysi
viru
isol
virolog
data
set
questionnair
detail
clinic
cours
ill
episod
return
particip
viru
sampl
associ
questionnair
questionnair
data
set
figur
demograph
characterist
individu
particip
two
studi
popul
summaris
tabl
number
particip
factor
associ
increas
probabl
complet
questionnair
femal
sex
rr
p
older
age
p
omnibu
test
across
age
categori
versu
questionnair
complet
vaccin
rr
p
similarli
omnibu
test
associ
smoke
statist
signific
p
proport
never
smoke
similar
versu
two
data
set
known
viru
identifi
specimen
virolog
data
set
virus
list
tabl
togeth
group
purpos
analysi
given
small
number
mani
instanc
overal
distribut
virus
isol
group
vari
substanti
month
collect
picornavirus
common
may
coronavirus
isol
predominantli
influenza
virus
detect
primarili
figur
associ
sought
rang
particip
variabl
posit
viru
identif
consid
ill
episod
primari
unit
analysi
adjust
month
collect
studi
site
tabl
adult
age
year
year
significantli
less
like
viru
detect
pcr
refer
age
group
year
specimen
posit
associ
time
gap
ili
onset
specimen
collect
consist
throughout
studi
period
effect
month
observ
note
three
four
highest
recruit
site
report
significantli
lower
adjust
odd
ratio
detect
viru
specimen
return
result
compar
fourth
refer
site
specimen
test
posit
data
shown
seen
tabl
particip
characterist
associ
detect
one
viru
group
anoth
predict
except
influenza
vaccin
statu
univari
logist
regress
model
vaccin
statu
outcom
variabl
individu
test
posit
influenza
virus
significantli
less
like
immunis
refer
viru
neg
popul
p
indic
protect
effect
ili
vaccin
also
trend
toward
higher
immunis
coverag
among
picornavirus
detect
p
given
associ
refer
viru
neg
vaccin
p
find
indic
associ
picornaviru
detect
vaccin
particip
prior
influenza
season
defin
month
august
septemb
associ
picornaviru
detect
influenza
vaccin
evid
p
follow
season
associ
stronger
p
individu
symptom
report
particip
episod
summaris
tabl
along
medic
diagnos
complic
ili
particip
experienc
repeat
infect
studi
period
two
episod
three
episod
three
subject
viru
group
picornavirus
isol
one
occas
two
particip
instanc
week
apart
justifi
consider
independ
event
median
durat
ill
day
rang
signific
variat
viru
type
data
shown
median
time
spent
away
usual
activ
day
rang
increas
mean
day
p
episod
associ
isol
influenza
compar
episod
isol
univari
linear
regress
model
episod
medic
attend
visit
gener
practition
associ
viru
type
observ
logist
regress
data
shown
thirteen
particip
prescrib
antivir
medic
none
hospitalis
small
number
record
medic
diagnos
complic
tabl
prevent
detail
analysi
associ
viru
isol
note
weak
suggest
bronchiti
chest
infect
common
particip
influenza
overal
cf
tabl
observ
valu
symptom
score
normal
distribut
mean
sd
median
rang
associ
sought
continu
outcom
viru
particip
characterist
multivari
linear
regress
model
adjust
month
site
specimen
collect
tabl
mean
symptom
score
report
individu
influenza
significantli
higher
observ
ili
attribut
infecti
caus
viru
detect
score
attenu
vaccin
statu
post
hoc
subgroup
analysi
restrict
episod
vaccin
mean
score
unvaccin
mean
score
differ
ci
p
asian
particip
report
significantli
fewer
symptom
caucasian
present
asian
mean
score
caucasian
mean
score
differ
ci
p
asian
particip
influenza
complet
questionnair
prevent
analysi
symptom
score
consist
throughout
year
effect
month
present
observ
particip
two
studi
site
report
significantli
higher
symptom
score
centr
inspect
result
like
due
small
number
involv
total
particip
three
influenza
cours
studi
period
approxim
particip
present
ili
evalu
half
provid
addit
inform
cours
diseas
known
viru
identifi
sampl
vari
detect
rate
age
site
isol
undetect
viru
distinguish
inadequ
sampl
particip
issu
relat
transport
sampl
presenc
unknown
viru
picornavirus
common
virus
observ
follow
influenza
influenza
confirm
approxim
particip
influenza
season
australia
particularli
mild
follow
notabl
sever
season
epidem
given
howev
acknowledg
may
occur
result
subclin
infect
potenti
failur
particip
report
mild
symptom
despit
intens
consist
expect
find
healthi
children
influenza
associ
higher
sever
influenza
associ
higher
composit
symptom
score
vaccin
provid
partial
protect
ili
associ
influenza
evid
diseas
modif
measur
symptom
score
particip
breakthrough
symptomat
infect
specul
may
due
infect
strain
influenza
cover
vaccin
studi
household
transmiss
prepar
use
questionnair
data
set
find
evid
consist
hypothesi
although
without
viru
type
subject
hypothesi
scrutini
observ
associ
vaccin
isol
picornavirus
perhap
suggest
picornavirus
fill
nich
vacat
exclus
influenza
owe
vaccin
consist
hypothesi
viral
interfer
support
associ
present
follow
influenza
season
prior
season
consist
interfer
effect
although
exclud
explan
includ
simpl
statist
fluctuat
studi
conduct
within
larg
commun
dwell
cohort
healthi
adult
use
sensit
ie
inclus
ili
case
definit
ascertain
present
across
full
spectrum
symptomat
diseas
therefor
complement
protocol
focus
individu
underli
respiratori
disord
present
medic
care
outpati
hospit
set
provid
comprehens
pictur
spectrum
symptomat
diseas
diagnost
method
pcr
employ
high
specif
allow
us
test
larg
number
recent
describ
pathogen
reduc
probabl
return
neg
result
studi
conduct
within
trial
vaccin
effect
necessarili
constrain
primari
protocol
degre
particip
select
healthi
without
underli
condit
would
result
routin
recommend
annual
influenza
vaccin
given
studi
design
studi
popul
vari
gener
popul
younger
less
like
smoke
like
women
furthermor
studi
popul
return
questionnair
enabl
examin
symptom
score
bias
toward
women
year
particip
immunis
influenza
associ
anticip
reduct
influenza
case
vaccin
proport
swab
collect
individu
present
ili
evalu
control
popul
limit
abil
assert
pathogen
virus
detect
restrict
comparison
symptom
score
viru
infect
event
particip
met
report
ili
case
definit
studi
conduct
use
gener
practic
sentinel
surveil
scheme
victoria
australia
year
show
similar
overal
rate
viru
detect
ili
submit
swab
ili
report
gp
studi
despit
smaller
number
virus
test
studi
specimen
posit
influenza
compar
mix
virus
detect
particip
studi
present
gp
similar
full
data
set
data
shown
discrep
perhap
reflect
natur
ili
definit
use
studi
potenti
bia
ili
chosen
swab
gp
studi
grant
et
al
compar
studi
respiratori
virus
involv
exacerb
chronic
obstruct
pulmonari
diseas
copd
conduct
melbourn
australia
overal
rate
viru
detect
higher
exacerb
studi
distribut
virus
preponder
picornavirus
influenza
similar
studi
confirm
far
greater
odd
viru
detect
individu
symptom
match
control
provid
prior
evid
aetiolog
role
virus
ill
exacerb
similar
studi
germani
picornavirus
influenza
rsv
commonli
caus
diseas
among
patient
copd
belfast
rhinovirus
adenoviru
frequent
associ
increas
respiratori
difficulti
studi
similar
patient
popul
hong
kong
reveal
far
lower
burden
picornavirus
rhinoviru
perhap
reflect
true
differ
epidemiolog
differ
sensit
detect
method
find
add
evolv
knowledg
base
regard
experi
rang
respiratori
virus
australia
particular
confirm
distinct
influenza
pathogen
measur
symptom
score
even
among
healthi
individu
led
call
expans
fund
immunis
recommend
australia
reduc
spread
diseas
data
requir
fill
exist
knowledg
gap
regard
commun
burden
diseas
inform
robust
estim
like
strategi
work
consid
impact
infect
introduct
examin
pattern
secondari
transmiss
describ
particip
questionnair
identifi
specimen
test
neg
known
virus
next
phase
project
involv
discoveri
hitherto
unknown
respiratori
virus
use
viral
molecular
detect
method
peter
howard
jame
mccaw
jodi
mcvernon
conduct
statist
analys
provid
primari
interpret
result
wrote
manuscript
peter
richmond
princip
investig
vaccin
efficaci
trial
within
substudi
conduct
terri
nolan
jodi
mcvernon
theo
sloot
michael
nissen
stephen
lambert
peter
richmond
conceiv
substudi
secur
fund
conduct
partnership
csl
limit
repres
michael
lai
michael
greenberg
jodi
mcvernon
coordin
conduct
studi
multipl
site
oversaw
collat
questionnair
data
theo
sloot
michael
nissen
stephen
lambert
oversaw
conduct
report
virolog
test
queensland
paediatr
infecti
diseas
laboratori
michael
lai
medic
monitor
main
vaccin
studi
partner
investig
substudi
michael
greenberg
author
contribut
critic
revis
manuscript
seen
approv
final
version
manuscript
mn
receiv
travel
grant
wyeth
australia
present
independ
research
intern
meet
current
previous
princip
investig
clinic
trial
sponsor
abbott
baxter
csl
gsk
medimmun
merck
novarti
wyeth
pfizer
